Competitor Analysis: IDO & TDO Inhibitors - Novel Immune Response Checkpoint Modulators
Competitor Analysis: IDO & TDO Inhibitors - Novel Immune Response Checkpoint Modulators
The Competitive Intelligence report about IDO & TDO Inhibitors - Novel Immune Response Checkpoint Modulators provides a competitor analysis as of March 2015 in the development pipeline of novel inhibitors of indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3- dioxygenase (TDO) for treatment of cancer as monotherapy and in combination with other immune checkpoint inhibitors. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report provides a compilation of active small molecule projects in research and development as specific IDO or TDO inhibitors as well as dual IDO & TDO inhibitors for treatment of cancer. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
The Competitive Intelligence report about IDO & TDO Inhibitors - Novel Immune Response Checkpoint Modulators provides a competitor analysis as of March 2015 in the development pipeline of novel inhibitors of indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3- dioxygenase (TDO) for treatment of cancer as monotherapy and in combination with other immune checkpoint inhibitors. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report provides a compilation of active small molecule projects in research and development as specific IDO or TDO inhibitors as well as dual IDO & TDO inhibitors for treatment of cancer. Competitor projects are listed in a tabular format providing information on:
- Drug Codes
- Target / Mechanism of Action
- Class of Compound
- Company
- Product Category
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Specific Indoleamine 2,3-Dioxygenase (IDO) Inhibitors
Specific Tryptophan 2,3Dioxygenase (TDO) Inhibitors
Dual IDO & TDO Inhibitors
Corporate IDO & TDO Inhibitor R&D Pipelines
Specific Tryptophan 2,3Dioxygenase (TDO) Inhibitors
Dual IDO & TDO Inhibitors
Corporate IDO & TDO Inhibitor R&D Pipelines
